Robert O. Cotes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert O. Cotes has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
- Emily Griner
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, USA
8 shared publications - Jonathan G. Leung
Department of Pharmacy, Mayo Clinic, Rochester, MN
7 shared publications - Gari D. Clifford
Emory University
6 shared publications - Salman Seyedi
Emory University, Atlanta, United States
6 shared publications - Zifan Jiang
Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA
6 shared publications - Ali Bahrami Rad
Emory University School of Medicine
5 shared publications
Latest Publications
- 22 October 2026
- Published by American Psychiatric Association Publishing in Psychiatric Services
Outdated Product Labeling and Implications for Contemporary Standards of Care: The Example of Clozapine
Discontinuation of the U.S. Food and Drug Administration's clozapine risk evaluation and mitigation strategy program led to a package insert (PI) revision in June 2025. However, that PI update retained many elements that are inconsistent with modern clozapine prescribing, including rapid titration, twice-daily dosing at the start of therapy, and titration without regard to patient factors (e.g., ancestry, sex and gender, or smoking status). The revision also provided no guidance on monitoring for myocarditis or mitigating the primary causes of mortality-pneumonia and ileus. This discrepancy between the clozapine PI and evidence-based practices has caused clinicians to consider whether deviation from the PI presents a medicolegal risk and how to cope with outdated PI information for clozapine and other medications. This article reviews the relative weight of different forms of medical evidence in establishing the standard of care, illustrates through case law that a PI does not define the standard of care and is inadmissible in malpractice litigation without expert testimony, and provides guidance for clinicians on how to navigate outdated, non-evidence-based PI recommendations. The information in this article should reassure clinicians that using modern evidence-based care-not archaic PI recommendations-is the optimal choice when treating patients.
- 22 October 2026
- Published by American Psychiatric Association Publishing in Psychiatric Services
Outdated Product Labeling and Implications for Contemporary Standards of Care: The Example of Clozapine
Discontinuation of the U.S. Food and Drug Administration's clozapine risk evaluation and mitigation strategy program led to a package insert (PI) revision in June 2025. However, that PI update retained many elements that are inconsistent with modern clozapine prescribing, including rapid titration, twice-daily dosing at the start of therapy, and titration without regard to patient factors (e.g., ancestry, sex and gender, or smoking status). The revision also provided no guidance on monitoring for myocarditis or mitigating the primary causes of mortality-pneumonia and ileus. This discrepancy between the clozapine PI and evidence-based practices has caused clinicians to consider whether deviation from the PI presents a medicolegal risk and how to cope with outdated PI information for clozapine and other medications. This article reviews the relative weight of different forms of medical evidence in establishing the standard of care, illustrates through case law that a PI does not define the standard of care and is inadmissible in malpractice litigation without expert testimony, and provides guidance for clinicians on how to navigate outdated, non-evidence-based PI recommendations. The information in this article should reassure clinicians that using modern evidence-based care-not archaic PI recommendations-is the optimal choice when treating patients.
- 22 October 2026
- Published by American Psychiatric Association Publishing in Psychiatric Services
The Rise of Medicare Advantage: Implications for Psychiatric Care
In light of the dramatic rise in Medicare Advantage (MA) enrollment over the past 20 years and the negative impacts of certain MA plans on accessibility, affordability, and equity in mental health care, the authors analyzed literature and publicly available data to explore the impacts of the expansion of MA on psychiatric care. A comprehensive search was conducted in PubMed between December 2025 and January 2026, and data from KFF published between 2021 and 2025 were analyzed to examine trends in MA with a particular focus on mental health. This analysis revealed that increased penetration of MA into the Medicare-eligible population worsened existing strains on psychiatric care through managed care practices that limited access, increased out-of-pocket costs, perpetuated inequity, and may have contributed to lower psychiatrist participation in the Medicare program. To better understand the consequences of MA's emerging predominance on psychiatric care, studies of care quality and outcomes must correct for diagnosis upcoding and selective enrollment in MA, which limit comparisons between MA and traditional Medicare. Efforts to address accessibility, affordability, and equity in MA must address narrow networks, high out-of-pocket costs, and prior authorization requirements in MA plans, which create barriers to accessing mental health care, especially for vulnerable populations.
- 22 October 2026
- Published by American Psychiatric Association Publishing in Psychiatric Services
The Rise of Medicare Advantage: Implications for Psychiatric Care
In light of the dramatic rise in Medicare Advantage (MA) enrollment over the past 20 years and the negative impacts of certain MA plans on accessibility, affordability, and equity in mental health care, the authors analyzed literature and publicly available data to explore the impacts of the expansion of MA on psychiatric care. A comprehensive search was conducted in PubMed between December 2025 and January 2026, and data from KFF published between 2021 and 2025 were analyzed to examine trends in MA with a particular focus on mental health. This analysis revealed that increased penetration of MA into the Medicare-eligible population worsened existing strains on psychiatric care through managed care practices that limited access, increased out-of-pocket costs, perpetuated inequity, and may have contributed to lower psychiatrist participation in the Medicare program. To better understand the consequences of MA's emerging predominance on psychiatric care, studies of care quality and outcomes must correct for diagnosis upcoding and selective enrollment in MA, which limit comparisons between MA and traditional Medicare. Efforts to address accessibility, affordability, and equity in MA must address narrow networks, high out-of-pocket costs, and prior authorization requirements in MA plans, which create barriers to accessing mental health care, especially for vulnerable populations.
- Open Access
International trends in clozapine utilisation prevalence in adults, adolescents and older people: An observational study in 42 countries between 2015–2024
Importance: Clozapine is the only evidence-based treatment for treatment-resistant schizophrenia (TRS), yet substantial international variation in its use has been reported. Objective: To provide a comprehensive and updated assessment of international clozapine utilisation by estimating prevalence across countries using a standardised methodology and examining factors associated with variation in use. Design, Setting, and Participants: Repeated cross-sectional study using population-based data from 2015 to 2024. Individual-level data were obtained from 36 countries and 1 special administrative region, supplemented by national clozapine consumption data from 5 additional countries. Analyses were conducted separately for adults (20-64 years; primary analysis), adolescents (10-19 years), and older adults (≥65 years). Main Outcomes and Measures: Annual outpatient clozapine utilisation prevalence per 100,000 population by age group, sex, country and calendar year. Associations between clozapine utilisation prevalence and country-level health system, demographic, and socioeconomic indicators were also examined. Results: We analysed data from more than 1.1 billion people across all inhabited continents. In 2024, crude adult clozapine use prevalence was highest in Croatia (415.3 per 100,000 population) and Finland (302.0 per 100,000), and lowest in Oman (0.5 per 100,000) and Ethiopia (0.3 per 100,000), representing a 1,384-fold difference. Across most countries, utilisation peaked among individuals aged 50 to 59 years. The male-to-female prevalence ratio ranged from 0.4 in the United Arab Emirates to 2.8 in Colombia. Among adolescents, prevalence was highest in Colombia (42.7 per 100,000) and Croatia (24.4 per 100,000), while among older adults it was highest in Croatia (406.9 per 100,000) and Iceland (339.7 per 100,000). Across all countries, adult clozapine utilisation increased by 17% (95% CI, 16%-18%), from 44.7 per 100,000 population (95% CI, 44.5-44.9) to 52.2 per 100,000 population (95% CI, 51.1-52.4). Country-specific trends ranged from a 71% decrease to a 342% increase. None of the examined indicators explained variation in clozapine utilisation across countries. Conclusion and relevance: Clozapine use increased modestly over the past decade but remained highly variable between countries. This variation was not explained by national socioeconomic, healthcare-system, or monitoring-related factors, suggesting an important role for clinical and service-level barriers. The concentration of clozapine use in later adulthood is consistent with delayed initiation and highlights opportunities to improve timely access to evidence-based treatment for TRS. Funding: Hsien-Yuan Lane: National Science and Technology Council, Taiwan (NSTC 114-2629-B-039-001-); The China Medical University Hospital Research Project (DMR-113-009 and DMR-114-046). Philippe Mortier: Miguel Servet grant CP21/00078 co–financed by the Instituto de Salud Carlos III (ISCIII) and co–funded by the European Union; grant PI22/00107 funded by ISCIII and co–funded by the European Union; and grant 202220–30–31 from the Fundació la Marató de TV3. Heidi Taipale: Sigrid Jusélius Foundation grant.
Open AccessInternational trends in clozapine utilisation prevalence in adults, adolescents and older people: An observational study in 42 countries between 2015–2024
Importance: Clozapine is the only evidence-based treatment for treatment-resistant schizophrenia (TRS), yet substantial international variation in its use has been reported. Objective: To provide a comprehensive and updated assessment of international clozapine utilisation by estimating prevalence across countries using a standardised methodology and examining factors associated with variation in use. Design, Setting, and Participants: Repeated cross-sectional study using population-based data from 2015 to 2024. Individual-level data were obtained from 36 countries and 1 special administrative region, supplemented by national clozapine consumption data from 5 additional countries. Analyses were conducted separately for adults (20-64 years; primary analysis), adolescents (10-19 years), and older adults (≥65 years). Main Outcomes and Measures: Annual outpatient clozapine utilisation prevalence per 100,000 population by age group, sex, country and calendar year. Associations between clozapine utilisation prevalence and country-level health system, demographic, and socioeconomic indicators were also examined. Results: We analysed data from more than 1.1 billion people across all inhabited continents. In 2024, crude adult clozapine use prevalence was highest in Croatia (415.3 per 100,000 population) and Finland (302.0 per 100,000), and lowest in Oman (0.5 per 100,000) and Ethiopia (0.3 per 100,000), representing a 1,384-fold difference. Across most countries, utilisation peaked among individuals aged 50 to 59 years. The male-to-female prevalence ratio ranged from 0.4 in the United Arab Emirates to 2.8 in Colombia. Among adolescents, prevalence was highest in Colombia (42.7 per 100,000) and Croatia (24.4 per 100,000), while among older adults it was highest in Croatia (406.9 per 100,000) and Iceland (339.7 per 100,000). Across all countries, adult clozapine utilisation increased by 17% (95% CI, 16%-18%), from 44.7 per 100,000 population (95% CI, 44.5-44.9) to 52.2 per 100,000 population (95% CI, 51.1-52.4). Country-specific trends ranged from a 71% decrease to a 342% increase. None of the examined indicators explained variation in clozapine utilisation across countries. Conclusion and relevance: Clozapine use increased modestly over the past decade but remained highly variable between countries. This variation was not explained by national socioeconomic, healthcare-system, or monitoring-related factors, suggesting an important role for clinical and service-level barriers. The concentration of clozapine use in later adulthood is consistent with delayed initiation and highlights opportunities to improve timely access to evidence-based treatment for TRS. Funding: Hsien-Yuan Lane: National Science and Technology Council, Taiwan (NSTC 114-2629-B-039-001-); The China Medical University Hospital Research Project (DMR-113-009 and DMR-114-046). Philippe Mortier: Miguel Servet grant CP21/00078 co–financed by the Instituto de Salud Carlos III (ISCIII) and co–funded by the European Union; grant PI22/00107 funded by ISCIII and co–funded by the European Union; and grant 202220–30–31 from the Fundació la Marató de TV3. Heidi Taipale: Sigrid Jusélius Foundation grant.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2026 (1)
Managing Recurrent Postictal Worsening of Psychosis in Clozapine‐Treated Schizophrenia: A Case Report
Postictal worsening of psychosis can be described as the development or exacerbation of psychotic symptoms following a seizure. Patients on clozapine for treatment‐resistant schizophrenia are at an increased risk for seizures and subsequent postictal worsening of psychosis. Because patients with schizophrenia may experience ongoing psychotic symptoms, it may be difficult to appreciate the development of postictal worsening of psychosis in these patients. We present the case of a 49‐year‐old woman with a longstanding history of schizophrenia treated with clozapine who presented to the emergency department (ED) after experiencing a seizure. In the following days, she and her mother reported an exacerbation of psychotic symptoms, which was ultimately attributed to a postictal worsening of psychosis. She was successfully treated after being prescribed an increased nightly dose of clozapine. This dose was eventually reduced to the usual dose she had been taking prior to the postictal exacerbation of psychosis. We also briefly describe a recurrent episode the patient experienced approximately 1 year later. This case contributes to the literature by offering one potential management strategy for postictal worsening of psychosis in a patient with a primary psychotic disorder.
- 1 January 2026
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2026 (1)
Open AccessManaging Recurrent Postictal Worsening of Psychosis in Clozapine‐Treated Schizophrenia: A Case Report
Postictal worsening of psychosis can be described as the development or exacerbation of psychotic symptoms following a seizure. Patients on clozapine for treatment‐resistant schizophrenia are at an increased risk for seizures and subsequent postictal worsening of psychosis. Because patients with schizophrenia may experience ongoing psychotic symptoms, it may be difficult to appreciate the development of postictal worsening of psychosis in these patients. We present the case of a 49‐year‐old woman with a longstanding history of schizophrenia treated with clozapine who presented to the emergency department (ED) after experiencing a seizure. In the following days, she and her mother reported an exacerbation of psychotic symptoms, which was ultimately attributed to a postictal worsening of psychosis. She was successfully treated after being prescribed an increased nightly dose of clozapine. This dose was eventually reduced to the usual dose she had been taking prior to the postictal exacerbation of psychosis. We also briefly describe a recurrent episode the patient experienced approximately 1 year later. This case contributes to the literature by offering one potential management strategy for postictal worsening of psychosis in a patient with a primary psychotic disorder.
- 1 November 2025
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 76 (11) , 1022-1026
A National Analysis of Facility-Level Clozapine Availability in U.S. Mental Health Services
Clozapine is highly effective but underutilized because of patient-, prescriber-, and system-related factors. The purpose of this study was to describe clozapine availability at U.S. mental health facilities. A cross-sectional analysis of the 2023 National Substance Use and Mental Health Services Survey was conducted. Clozapine availability was assessed along with facility characteristics associated with odds of clozapine prescription via logistic regression. Among facilities that prescribed antipsychotics (N=6,445), clozapine was available at 58% overall and at 64% that had a dedicated serious mental illness program. Psychiatric hospitals had the highest availability (80%). Outpatient facilities (adjusted odds ratio [AOR]=0.41, p=0.004) were less likely to offer clozapine, and those with serious mental illness programs (AOR=1.57, p<0.001), those with on-site laboratory testing (AOR=1.69, p<0.001), and those that accepted Medicare (AOR=1.92, p<0.001) were more likely to offer it. Limited facility-wide clozapine availability in many settings underscores the depth of its underutilization. Closing gaps in clozapine access will require targeted policy, quality improvement, and educational initiatives.
- 1 November 2025
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 76 (11) , 1022-1026
A National Analysis of Facility-Level Clozapine Availability in U.S. Mental Health Services
Clozapine is highly effective but underutilized because of patient-, prescriber-, and system-related factors. The purpose of this study was to describe clozapine availability at U.S. mental health facilities. A cross-sectional analysis of the 2023 National Substance Use and Mental Health Services Survey was conducted. Clozapine availability was assessed along with facility characteristics associated with odds of clozapine prescription via logistic regression. Among facilities that prescribed antipsychotics (N=6,445), clozapine was available at 58% overall and at 64% that had a dedicated serious mental illness program. Psychiatric hospitals had the highest availability (80%). Outpatient facilities (adjusted odds ratio [AOR]=0.41, p=0.004) were less likely to offer clozapine, and those with serious mental illness programs (AOR=1.57, p<0.001), those with on-site laboratory testing (AOR=1.69, p<0.001), and those that accepted Medicare (AOR=1.92, p<0.001) were more likely to offer it. Limited facility-wide clozapine availability in many settings underscores the depth of its underutilization. Closing gaps in clozapine access will require targeted policy, quality improvement, and educational initiatives.
- 1 October 2025
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 23 (4) , 375-388
A Call to Action for Starting Clozapine: Increasing Clozapine Use and Safety in a Post-REMS Era
Clozapine remains the only medication approved by the U.S. Food and Drug Administration (FDA) for managing treatment-resistant schizophrenia and for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. Despite its known benefits, its use remains suboptimal with non-evidence-based treatments often trialed before clozapine. These delays have been shown to reduce the likelihood of clozapine response or increase the risk of early discontinuation. With the elimination of the Clozapine Risk Evaluation and Mitigation Strategy program, one barrier that had impeded clozapine use has been negated. However, barriers persist that are related to clinicians' perceptions of clozapine and knowledge related to appropriate titration, monitoring, and management of adverse drug reactions. With a growing body of evidence suggesting that current FDA-recommended hematologic monitoring is overly cautious, there is future potential that these requirements become less stringent. This marks an important time to bring forth a call to action for increased use of clozapine and focus on important clozapine-related initiation and monitoring strategies. Such strategies include slower initial titration, understanding differences in clozapine metabolism across different genetic ancestry groups, awareness of inflammatory reactions, recognition of pneumonia-related mortality, and appropriate bowel care. This review highlights best and evidence-based practices to help clinicians increase clozapine prescribing and ensure that patients have the greatest opportunity for a successful, potentially life-saving clozapine trial.
- 1 October 2025
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 23 (4) , 375-388
A Call to Action for Starting Clozapine: Increasing Clozapine Use and Safety in a Post-REMS Era
Clozapine remains the only medication approved by the U.S. Food and Drug Administration (FDA) for managing treatment-resistant schizophrenia and for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. Despite its known benefits, its use remains suboptimal with non-evidence-based treatments often trialed before clozapine. These delays have been shown to reduce the likelihood of clozapine response or increase the risk of early discontinuation. With the elimination of the Clozapine Risk Evaluation and Mitigation Strategy program, one barrier that had impeded clozapine use has been negated. However, barriers persist that are related to clinicians' perceptions of clozapine and knowledge related to appropriate titration, monitoring, and management of adverse drug reactions. With a growing body of evidence suggesting that current FDA-recommended hematologic monitoring is overly cautious, there is future potential that these requirements become less stringent. This marks an important time to bring forth a call to action for increased use of clozapine and focus on important clozapine-related initiation and monitoring strategies. Such strategies include slower initial titration, understanding differences in clozapine metabolism across different genetic ancestry groups, awareness of inflammatory reactions, recognition of pneumonia-related mortality, and appropriate bowel care. This review highlights best and evidence-based practices to help clinicians increase clozapine prescribing and ensure that patients have the greatest opportunity for a successful, potentially life-saving clozapine trial.
- 1 October 2025
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 23 (4) , 373-374
Do We Now Have the Tools to Meaningfully Improve Outcomes for People With Schizophrenia?
- 1 October 2025
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 23 (4) , 373-374
Do We Now Have the Tools to Meaningfully Improve Outcomes for People With Schizophrenia?
- Open Access
- 5 June 2025
- Published by Springer Nature in Schizophrenia
- Vol. 11 (1) , 1-6
Enhancing social cognition in psychosis – the potential role of open dialogue
Research in psychotic conditions increasingly focuses on improving functional outcomes. While antipsychotic treatments can alleviate positive symptoms in some patients, they have limited impact on psychosocial function. Social cognition (SC) has emerged as a promising target for intervention, with multiple new approaches designed to enhance SC in psychotic conditions. However, the generalisability of these interventions to real-world functioning remains uncertain. We propose that the Finnish Open Dialogue (OD) approach may offer unique advantages for improving SC in individuals with psychosis and their families and suggest this as an important direction for future research. This commentary aims to bridge perspectives from SC research and OD practice, proposing avenues for integration and future research.
- 5 June 2025
- Published by Springer Nature in Schizophrenia
- Vol. 11 (1) , 1-6
Open AccessEnhancing social cognition in psychosis – the potential role of open dialogue
Research in psychotic conditions increasingly focuses on improving functional outcomes. While antipsychotic treatments can alleviate positive symptoms in some patients, they have limited impact on psychosocial function. Social cognition (SC) has emerged as a promising target for intervention, with multiple new approaches designed to enhance SC in psychotic conditions. However, the generalisability of these interventions to real-world functioning remains uncertain. We propose that the Finnish Open Dialogue (OD) approach may offer unique advantages for improving SC in individuals with psychosis and their families and suggest this as an important direction for future research. This commentary aims to bridge perspectives from SC research and OD practice, proposing avenues for integration and future research.
- 1 June 2025
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 76 (6) , 606-610
Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019–2023
PsychiatryOnline.org is the platform for all American Psychiatric Association Publishing journals, DSM, and bestselling textbooks, as well as APA Practice Guidelines, and continuing medical education.
- 1 June 2025
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 76 (6) , 606-610
Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019–2023
PsychiatryOnline.org is the platform for all American Psychiatric Association Publishing journals, DSM, and bestselling textbooks, as well as APA Practice Guidelines, and continuing medical education.
- Top Cited PapersOpen Access
- 9 April 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 45 (3) , 197-218
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
Purpose/Background: This is the second part of a 2-part article that proposes improving the United States (US) clozapine package insert. Part II focuses on fatal outcomes and the 5 boxed warnings, 4 specifically for clozapine: severe neutropenia, seizure, orthostatic hypotension and myocarditis, and 1 for all antipsychotics (elderly with dementia). Methods: US reports to the World Health Organization's global pharmacovigilance database were analyzed from clozapine's introduction to January 15, 2023. Findings/Results: The US was the top reporter worldwide for clozapine with 56,003 reports and 9587 associated fatal outcomes. The 4 clozapine boxed warnings were associated with 534 fatal outcomes (218 with severe neutropenia, 131 with seizures, 125 with orthostasis, 36 with myocarditis, 24 with cardiomyopathy, and 0 with mitral valve prolapse). With no boxed warnings, pneumonia was associated with 674 fatal outcomes and increased white blood cell count (a sign of infection) with 596 fatal outcomes. After considering overlaps, pneumonia and increases in white blood cell count explained 900 fatalities, or 9.4% of 9587 fatal outcomes. The Food and Drug Administration continues to focus on severe neutropenia which was associated with only 218 or 2.3% of fatal outcomes, whereas 97.7% of fatal outcomes reported in US clozapine-treated patients had another cause. Implications/Conclusions: To help prevent future deaths in clozapine-treated patients, the clozapine package insert should focus on fatal outcomes during infections. Part II offers detailed solutions regarding current boxed warnings and lack of a warning for pneumonia and other infections. The Supplementary Material includes letters of support from 124 non-US clozapine experts from 44 countries/regions who support Parts I and II.
- 9 April 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 45 (3) , 197-218
Top Cited PapersOpen AccessLetter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
Purpose/Background: This is the second part of a 2-part article that proposes improving the United States (US) clozapine package insert. Part II focuses on fatal outcomes and the 5 boxed warnings, 4 specifically for clozapine: severe neutropenia, seizure, orthostatic hypotension and myocarditis, and 1 for all antipsychotics (elderly with dementia). Methods: US reports to the World Health Organization's global pharmacovigilance database were analyzed from clozapine's introduction to January 15, 2023. Findings/Results: The US was the top reporter worldwide for clozapine with 56,003 reports and 9587 associated fatal outcomes. The 4 clozapine boxed warnings were associated with 534 fatal outcomes (218 with severe neutropenia, 131 with seizures, 125 with orthostasis, 36 with myocarditis, 24 with cardiomyopathy, and 0 with mitral valve prolapse). With no boxed warnings, pneumonia was associated with 674 fatal outcomes and increased white blood cell count (a sign of infection) with 596 fatal outcomes. After considering overlaps, pneumonia and increases in white blood cell count explained 900 fatalities, or 9.4% of 9587 fatal outcomes. The Food and Drug Administration continues to focus on severe neutropenia which was associated with only 218 or 2.3% of fatal outcomes, whereas 97.7% of fatal outcomes reported in US clozapine-treated patients had another cause. Implications/Conclusions: To help prevent future deaths in clozapine-treated patients, the clozapine package insert should focus on fatal outcomes during infections. Part II offers detailed solutions regarding current boxed warnings and lack of a warning for pneumonia and other infections. The Supplementary Material includes letters of support from 124 non-US clozapine experts from 44 countries/regions who support Parts I and II.